Publication | Closed Access

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

Breast OncologyOncologyBreast CancerPharmacotherapyCancer TreatmentMedicineRadiation OncologyPhase 1Trastuzumab Emtansine